Biovail Corporation, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products used in the treatment of specialty central nervous system disorders. Its product portfolio includes Wellbutrin XL for the treatment of depression in adults; Xenazine for the treatment of chorea associated with Huntington's disease; Aplenzin for the treatment of major depressive disorder; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; Ultram ER for the management of chronic pain in adults; and Cardizem LA that provides blood pressure control. The company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Glumetza for the control of hyperglycemia in adult patients with type 2 diabetes; Ralivia for the management of pain of moderate severity; Nitoman for the treatment of hyperkinetic movement disorders; Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; and Zyban for smoking cessation treatment. In addition, it distributes various other pharmaceutical products, including Ativan for the management of anxiety disorders; Vasotec and Vaseretic for the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company’s generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties. The company distributes its products primarily through third party commercialization relationships in the United States and Canada. Biovail Corporation was founded in 1983 and is headquartered in Mississauga, Canada.

Penwest Pharmaceuticals Co. develops pharmaceutical products based on drug delivery technologies with focus on products that address disorders of the nervous system. Its proprietary drug delivery technologies include TIMERx, a controlled-release technology; Geminex, a technology enabling drug release at two different rates; SyncroDose, a technology enabling controlled release at the appropriate site in the body; and GastroDose system, a technology enabling drug delivery to the upper gastrointestinal tract. The company offers Opana ER, an oral extended release opioid analgesic for patients with moderate to severe pain requiring continuous opioid treatment using its TIMERx drug delivery technology; and Nifedipine XL for the treatment of hypertension and angina. Its products under development include Nalbuphine ER, a Phase IIa clinical trail product for the treatment of moderate chronic pain; and A0001, a Phase Ib clinical trail product for the treatment of diseases related to the inherited mitochondrial respiratory chain. Penwest Pharmaceuticals Co. has strategic alliance agreement with Endo Pharmaceuticals, Inc. for the development of Opana ER; collaboration and licensing agreement with Edison Pharmaceuticals, Inc. for the development of A0001 and up to one additional drug candidate of Edison’s.; and collaboration agreement with Mylan Pharmaceuticals Inc. for the development of Nifedipine XL. It also has a research and development agreement with Otsuka Pharmaceutical Co. Ltd. to develop a formulation of Otsuka compound utilizing the company’s TIMERx drug delivery technology. The company was founded in 1991 and is based Danbury, Connecticut. Penwest Pharmaceuticals Co. (NasdaqNM:PPCO) operates independently of Penford Corp. as of August 31, 1998.